Dauntless Pharmaceuticals has initiated a Phase 1 clinical study of its DP1038 intranasal octreotide acetate, the company said. The study will compare DP1038 to Sandostatin octreotide acetate injection in healthy volunteers. DP1038 is in development for the treatment of acromegaly and neuroendocrine tumors. In July 2014, Aegis Therapeutics announced that it was … [Read more...] about Dauntless Pharmaceuticals initiates Phase 1 study of intranasal octreotide
Medical
Windtree says aerosolized KL4 surfactant shows promise for treatment of flu in pre-clinical study
Windtree Therapeutics says a pre-clinical study in ferrets exposed to influenza demonstrated that the company's aerosolized KL4 surfactant increased survival and reduced lung inflammation, although the increase in survival rate was less than that for animals treated with oseltamivir (Tamiflu). Fewer clinical signs of influenza were observed in animals treated with KL4 … [Read more...] about Windtree says aerosolized KL4 surfactant shows promise for treatment of flu in pre-clinical study
Prevacus announces plans for Phase 1 study of PRV-002 intranasal therapy for concussion
Prevacus has announced that it plans to initiate a Phase 1 clinical trial of its PRV-002 intranasal product for the treatment of mild traumatic brain injury (mTBI) by the middle of 2017. According to the company, pre-clinical studies showed that intranasal administration of PRV-002 positively impacted memory, sensory-motor function, cerebral edema, anxiety and … [Read more...] about Prevacus announces plans for Phase 1 study of PRV-002 intranasal therapy for concussion
Spyryx Biosciences announces positive results from Phase 1 study of SPX-101
According to Spyryx Biosciences, a Phase 1 study of its SPX-101, an inhaled SPLUNC1-derived peptide that the company is developing for the treatment of cystic fibrosis, showed that the drug was well tolerated, with no reduction in lung function and no dose-limiting adverse effects. Based on those results, the company is planning a Phase 2 study in CF patients. The … [Read more...] about Spyryx Biosciences announces positive results from Phase 1 study of SPX-101
MannKind launches Afrezza titration pack, expands sales force
MannKind Corporation has announced the availability of a new titration pack which includes 60 each of 4, 8, and 12 unit cartridges of Afrezza inhalation powder. The company already offers a titration pack that includes 90 each of 4 and 8 unit cartridges, which it says accounts for nearly 25% of Afrezza units dispensed on a weekly basis. According to the company, … [Read more...] about MannKind launches Afrezza titration pack, expands sales force
Promising data from preclinical study of intranasal therapy for optic neuritis
Noveome Biotherapeutics has announced the publication of promising data from a preclinical study of its ST266 intranasal secretome showing anti-inflammatory activity and retinal ganglion cell (RGC) retention in the optic nerve in a mouse multiple sclerosis model. The article, titled, “Intranasal Delivery of a Novel Amnion Cell Secretome Prevents Neuronal Damage and … [Read more...] about Promising data from preclinical study of intranasal therapy for optic neuritis
Cipla launches the Synchrobreathe inhaler in South Africa
Cipla has launched its Synchrobreathe breath actuated inhaler in South Africa, the company announced. In 2015, Cipla had said that it expected to launch the inhaler by the end of that year. Cipla Medpro CEO Paul Miller said, “Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South … [Read more...] about Cipla launches the Synchrobreathe inhaler in South Africa
GSK initiates Phase 3 study of triple therapy DPI for the treatment of asthma
GlaxoSmithKline and Innoviva have announced the initiation of a Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol DPI compared to Relvar/Breo Ellipta for the treatment of asthma. GSK recently filed regulatory submissions for the FF/UMEC/VI DPI for the treatment of COPD in the United States and in the European Union. The Clinical study of Asthma … [Read more...] about GSK initiates Phase 3 study of triple therapy DPI for the treatment of asthma
Aradigm announces top line results from Phase 3 trials of Pulmaquin for non-CF bronchiectasis
Aradigm Corporation has announced that top-line results from the Phase 3 ORBIT-3 and ORBIT-4 trials of Pulmaquin inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis bronchiectasis (non-CF BE) demonstrated increase in time to the first exacerbation, the primary endpoint, that was not statistically significant in … [Read more...] about Aradigm announces top line results from Phase 3 trials of Pulmaquin for non-CF bronchiectasis
Study shows significant reduction in hospitalizations for children using Smartinhaler
Results from a study of Adherium's Smartinhaler adherence monitoring system showing a 5-fold reduction in hospitalizations over a one-year period for children with poorly controlled asthma who used the device have been published online by the journal Thorax. The STAAR study also found that adherence among the 38 children who completed the study using the … [Read more...] about Study shows significant reduction in hospitalizations for children using Smartinhaler